Evotec, Bristol Myers Squibb Protein Degradation Partnership Receives Second FDA Investigational New Drug Acceptance For CELMoD Candidate, Phase 1 Expected In 2027

Benzinga · 2d ago
  • FDA clearance expands partnered molecular glue pipeline
  • Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high unmet need